Galectin

Investigators identified tumor necrosis factor receptor 1 as the most frequently studied plasma biomarker in the setting of chronic kidney disease progression.

The influence of blood group on COVID-19 susceptibility and severity has been studied extensively since the start of the pandemic, with inconsistent results.